Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...
Merck KGaA, Darmstadt, Germany, a leading scien...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States a...
DLH (NASDAQ:DLHC) serves federal government cli...
RTI Surgical Holdings, Inc. is a leading global surgical implant company providing...
RTI Surgical Holdings, Inc. is a leading global...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
We are a leading, rapidly growing synthetic biology company that has developed a d...
We are a leading, rapidly growing synthetic bio...
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
The next evolution in DNA-based diagnostics. MicroGen Vet is the exclusive reselle...
The next evolution in DNA-based diagnostics. Mi...
Together, a potent new drug and a blood test to guide its use can be a life change...
Together, a potent new drug and a blood test to...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Join the National Investor Network and get the latest information with your interests in mind.